Canaccord Genuity Morning Coffee on Sanofi (SNY): Best Words In The English Language: It's Benign
Tweet Send to a FriendGet Alerts SNY Hot Sheet
Price: $54.86 +0.55%
Rating Summary:
7 Buy, 3 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
7 Buy, 3 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade SNY Now!
Canaccord Genuity Morning Coffee on Sanofi (NYSE: SNY): Best words in the English language: It's benign.
Sanofi’s best-selling diabetes treatment, Lantus, leads to no increased cancer risk, according to three large-scale studies in Europe and U.S. that explored a possible link among patients after one to three years of treatment. The studies, which analyzed data on more than 615,000 patients, independently compared the use of Lantus with other long-acting insulins in diabetics, the American Diabetes Association said in a statement. The results were presented Monday at the organization’s annual meeting in Philadelphia. Worldwide, Lantus has 80% of the market for long-acting, or basal, insulins used to treat diabetes and the product had sales of around 3.9 billion euros ($4.9 billion) last year, representing 12% of Sanofi's total sales. Only one of the studies found a “suggestion” of a link between Lantus and a modest increase in breast cancer, but only among new insulin users, researchers said. When another methodology was adopted, no such suggestion existed. The medicine maker is particularly reliant on Lantus because it faces a wave of patent expirations on other blockbuster medicines.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Sanofi’s best-selling diabetes treatment, Lantus, leads to no increased cancer risk, according to three large-scale studies in Europe and U.S. that explored a possible link among patients after one to three years of treatment. The studies, which analyzed data on more than 615,000 patients, independently compared the use of Lantus with other long-acting insulins in diabetics, the American Diabetes Association said in a statement. The results were presented Monday at the organization’s annual meeting in Philadelphia. Worldwide, Lantus has 80% of the market for long-acting, or basal, insulins used to treat diabetes and the product had sales of around 3.9 billion euros ($4.9 billion) last year, representing 12% of Sanofi's total sales. Only one of the studies found a “suggestion” of a link between Lantus and a modest increase in breast cancer, but only among new insulin users, researchers said. When another methodology was adopted, no such suggestion existed. The medicine maker is particularly reliant on Lantus because it faces a wave of patent expirations on other blockbuster medicines.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Janney Capital Trims Numbers on Buckle (BKE), Margins Peaking
- Dollar Tree (DLTR) Beats But Looks Stretched - Jefferies
- UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
Create E-mail Alert Related Categories
Analyst Comments
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
